JCO Oncology Practice

OCT 12, 2026 · JOURNAL ARTICLE

Participation of Patients With Gynecologic Cancer in Phase I Clinical Trials: Experience From Two National Cancer Institute–Designated Comprehensive Cancer Centers

JCO Oncology Practice

Purpose Phase I trials are intended to define the safety of novel therapeutics, yet they offer alternative options long before they are approved. Limited data exist regarding acces

OCT 5, 2026 · JOURNAL ARTICLE

Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors

JCO Oncology Practice

To review the safety, efficacy, and clinical considerations of vaginal estrogen therapy for the treatment of genitourinary syndrome of menopause (GSM) in patients with a history of

OCT 2, 2026 · JOURNAL ARTICLE

Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management

JCO Oncology Practice

Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases t

SEP 29, 2026 · JOURNAL ARTICLE

Contemporary Patterns of Medicare Part B Spending on Immune Checkpoint Inhibitors (2018-2022)

JCO Oncology Practice

PURPOSE Immune checkpoint inhibitors (ICIs) have transformed cancer care but impose a growing financial burden on Medicare. We characterized Medicare Part B spending and utilizatio

SEP 28, 2026 · JOURNAL ARTICLE

Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy

JCO Oncology Practice

Importance Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatme

SEP 23, 2026 · JOURNAL ARTICLE

Financial Toxicity and Quality of Life After Bone Marrow Transplant: A Longitudinal, Prospective Study

JCO Oncology Practice

PURPOSE Financial toxicity is common after bone marrow transplant (BMT) and is associated with worse quality of life, but longitudinal patterns remain poorly understood. METHODS We

SEP 4, 2026 · JOURNAL ARTICLE

Characterizing Time Toxicity in Lung Cancer Clinical Trials: Development and Application of a Novel Time Burden Metric

JCO Oncology Practice

Descriptive analysis of protocol-derived metrics across historical trials with no patient-level validation, establishing feasibility of a novel measurement framework rather than testing clinical impact.

AUG 19, 2026 · JOURNAL ARTICLE

Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies

JCO Oncology Practice

Expert consensus and implementation guidance on clinical translation of CRISPR-based therapy in hemoglobinopathies with established regulatory approval, addressing delivery, patient selection, and barriers to practice integration.